MedTrace Logo

Effect of Itopride on Semaglutide Gastroparesis

NCT07254715 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-11-28

No results posted yet for this study

Summary

Semaglutide delays gastric emptying and increases the risk of aspiration with anesthesia; So, the addition of prokinetics as Itopride, could enhance gastric emptying and hasten surgery.

The investigator will evaluate the effect of Itopride on Semaglutide-induced gastroparesis and residual gastric contents after 8 hours of fasting by gastric ultrasound before anesthesia.

Conditions

  • Semaglutide-Induced Gastric Motility
  • Anesthesia

Interventions

DRUG

Itopride HCI 50 mg

Daily oral 50mg Itopride tablet TID, 1 hour before meals for 7 days

DRUG

Placebo

Daily placebo tablet TID, 1 hour before meals for 7 days

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-31
Primary Completion
2026-04-30
Completion
2026-04-30

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07254715 on ClinicalTrials.gov